Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Profit After Tax: 2019-2025

Historic Profit After Tax for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to -$82.2 million.

  • Kymera Therapeutics' Profit After Tax fell 31.51% to -$82.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$295.1 million, marking a year-over-year decrease of 76.22%. This contributed to the annual value of -$223.9 million for FY2024, which is 52.32% down from last year.
  • Per Kymera Therapeutics' latest filing, its Profit After Tax stood at -$82.2 million for Q3 2025, which was down 7.26% from -$76.6 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Profit After Tax registered a high of -$13.1 million during Q1 2021, and its lowest value of -$82.2 million during Q3 2025.
  • Over the past 3 years, Kymera Therapeutics' median Profit After Tax value was -$52.9 million (recorded in 2023), while the average stood at -$54.1 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first spiked by 58.79% in 2023, then plummeted by 392.43% in 2024.
  • Quarterly analysis of 5 years shows Kymera Therapeutics' Profit After Tax stood at -$33.9 million in 2021, then dropped by 2.85% to -$34.9 million in 2022, then spiked by 58.79% to -$14.4 million in 2023, then plummeted by 392.43% to -$70.8 million in 2024, then tumbled by 31.51% to -$82.2 million in 2025.
  • Its Profit After Tax was -$82.2 million in Q3 2025, compared to -$76.6 million in Q2 2025 and -$65.6 million in Q1 2025.